US-based Ambrx and China-based Zhejiang Medicine have collaborated to develop and commercialize ARX788, an antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per the deal, both the companies will advance the product ...
Astellas Pharma and Ambrx have collaborated to discover and develop new antibody drug conjugates (ADCs) for the targeted delivery of drugs into cancer tissues. Ambrx will use site-specific conjugation technology in addition to proprietary ...
Tags: Antibody Drug, Health, Medicine